US OptionsDetailed Quotes

CNTA241220C20000

Watchlist

0.40
0.000.00%

15min DelayTrading Dec 3 10:17 ET

0.00High0.00Low

Centessa Pharmaceuticals Stock Discussion

Stock_Drift

Sep 26 05:05

$Centessa Pharmaceuticals (CNTA.US)$

Trytosaveabit

Apr 23 15:37

Update

$Centessa Pharmaceuticals (CNTA.US)$ Press Release: Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
Dow Jones· 15 mins ago
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for p...

Trytosaveabit

Apr 22 06:10

Update

$Centessa Pharmaceuticals (CNTA.US)$ The FDA Has Cleared Centessa Pharmaceuticals' Investigational New Drug Application To Initiate A Phase 1 First-in-human, Clinical Trial Of ORX750 For Narcolepsy

Meltyy

Apr 2 22:13

Gear up for AACR24!

See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...

JESSE JAMES8832

Feb 10 10:15

buy

$Centessa Pharmaceuticals (CNTA.US)$

Trytosaveabit

Dec 10, 2023 12:04

Update

$Centessa Pharmaceuticals (CNTA.US)$ BOSTON and LONDON, Dec. 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia. The data were shared in a poster presentation at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10, 2023. SerpinPC is an investigational subcutaneously...

Moomoo Breakfast US

Sep 12, 2022 07:36

Columns Today's Pre-Market Stock Movers: BMY, ADBE, MSTR, AZN and More

Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology (CLVS.US)$ +11.3%, $Cardiff Oncology (CRDF.US)$ +9%, $Immatics (IMTX.US)$ +8.3%, $IDEAYA Biosciences (IDYA.US)$ +8%, $Lyra Therapeutics (LYRA.US)$ +5.7%, $POINT Biopharma (PNT.US)$ +5.7%, $Edgewise Therapeutics (EWTX.US)$ +4.7%, $Concert Pharmaceuticals (CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals (DCPH.US)$ +3.2%, $Veracyte (VCYT.US)$ +2.6%, $SpringWorks Therapeutics (SWTX.US)$ +2.3%,...

Analysts Notebook

Jun 17, 2022 06:11

Columns Top upgrades and downgrades on 6/17: RBLX, AXP, CVS, GRAB and more

Upgrades
• $American Express (AXP.US)$ : Baird Upgrades to Outperform from Neutral - PT $175
• $The AZEK (AZEK.US)$ : BofA Securities Upgrades to Buy from Neutral
• $Capital One Financial (COF.US)$ : Baird Upgrades to Outperform from Neutral - PT $145
• $Fifth Third Bancorp (FITB.US)$ : Baird Upgrades to Outperform from Neutral - PT $44
• $M&T Bank (MTB.US)$ : Baird Upgrades to Outperform from Neutral - PT $200 (from $175)
• $NextEra Energy Partners LP (NEP.US)$ : RBC Cap...

Moomoo Breakfast US

Jun 2, 2022 07:27

Columns Today's pre-market stock movers: CHWY, PATH, SNAP, HPE and more

Gainers:
• $Repare Therapeutics (RPTX.US)$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy (CHWY.US)$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath (PATH.US)$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage (PSTG.US)$ +10.6% (In reaction to earnings)
• $Credo Technology (CRDO.US)$ +10.2% (In reaction ...

JulianMackie

Oct 19, 2021 03:41

$Centessa Pharmaceuticals (CNTA.US)$ and $Schrodinger (SDGR.US)$ will collaborate to discover therapies targeting the Orexin-2 receptor for sleep disorders.
The agreement will give Centessa subsidiary Orexia Therapeutics access to Schrodinger's computing platform. The platform allows for high performance computing in order to accurately predict the effectiveness of the target of interest.
The terms require Orexia to handle preclinical research activities, clinical development, and commercialization of potential candidates.

No comment yet